SPUNOLEUCEL
UNII EVQ94BW5G4

Substance Identification & Data

This profile provides standardized clinical and technical data for Spunoleucel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) EVQ94BW5G4.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

EVQ94BW5G4

CAS Registry Number

N/A

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

SPUNOLEUCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C180636

National Cancer Institute reference terminology for clinical and research data.

INN ID

12976

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

KL-230

Identifier assigned by the United States Adopted Names Council.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Spunoleucel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

SPUNOLEUCEL

Common Names & Synonyms

ALLOGENEIC MULTI-VIRUS SPECIFIC T LYMPHOCYTES TARGETING RESPIRATORY SYNCYTIAL VIRUS (RSV), INFLUENZA, PARAINFLUENZA VIRUS (PIV), AND HUMAN METAPNEUMOVIRUS (HMPV)

ALVR106 IS A NOVEL VIRUS-SPECIFIC CELL-BASED THERAPY TO TREAT FOUR RESPIRATORY VIRAL INFECTIONS THAT ARE A SERIOUS CAUSE OF MORBIDITY AND MORTALITY IN IMMUNOCOMPROMISED PATIENTS. ALVR106 IS UNDER DEVELOPMENT TO TREAT FOUR RESPIRATORY VIRAL INFECTIONS (RESPIRATORY SYNCYTIAL VIRUS, INFLUENZA, PARAINFLUENZA VIRUS AND HUMAN METAPNEUMOVIRUS) THAT ARE COMMON AND OF SIGNIFICANT CLINICAL CONCERN IN IMMUNOCOMPROMISED PATIENTS, INCLUDING THOSE WHO HAVE UNDERGONE HEMATOPOIETIC STEM CELL TRANSPLANTATION, SOLID ORGAN TRANSPLANTATION, AS WELL AS IN VULNERABLE ELDERLY AND PEDIATRIC POPULATIONS

ALVR106 IS A POLYCLONAL (CD4+ AND CD8+) VIRUS-SPECIFIC T CELL PRODUCT CONTAINING CELLS THAT ARE REACTIVE AGAINST FOUR VIRUSES (RSV, INFLUENZA, PIV, AND HMPV). THE CELLS ARE DERIVED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) FROM DONORS SEROPOSITIVE FOR ALL FOUR OF THESE VIRUSES

ALVR106 IS COMPRISED OF BOTH CD8+ AND CD4+ VIRUS-SPECIFIC T CELLS CAPABLE OF RECOGNIZING ACTIVELY REPLICATING VIRUS-INFECTED CELLS, PROLIFERATING IN RESPONSE TO ANTIGENIC STIMULATION AND MEDIATING ANTIVIRAL EFFECTS INCLUDING THE PRODUCTION OF CYTOKINES AND EFFECTOR MOLECULES, KILLING OF INFECTED CELLS IN PATIENTS WITH INFECTIONS/DISEASES ASSOCIATED WITH THE TARGET VIRUSES

SPUNOLEUCEL [INN]

SPUNOLEUCEL [USAN]

Technical Codes

ALV-106

ALVR106

External Clinical & Regulatory Resources

Previous UNIIEVQ6RX7DAN

Next UNIIEVR4295G77